| Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis S Leucht, A Cipriani, L Spineli, D Mavridis, D Örey, F Richter, M Samara, ... The Lancet 382 (9896), 951-962, 2013 | 2992 | 2013 |
| Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis M Huhn, A Nikolakopoulou, J Schneider-Thoma, M Krause, M Samara, ... The Lancet 394 (10202), 939-951, 2019 | 1292 | 2019 |
| Dose equivalents for antipsychotic drugs: the DDD method S Leucht, M Samara, S Heres, JM Davis Schizophrenia bulletin 42 (suppl_1), S90-S94, 2016 | 569 | 2016 |
| Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors S Leucht, C Leucht, M Huhn, A Chaimani, D Mavridis, B Helfer, M Samara, ... American Journal of Psychiatry 174 (10), 927-942, 2017 | 535 | 2017 |
| Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses M Huhn, M Tardy, LM Spineli, W Kissling, H Foerstl, G Pitschel-Walz, ... JAMA psychiatry 71 (6), 706-715, 2014 | 452 | 2014 |
| Dose equivalents for second-generation antipsychotics: the minimum effective dose method S Leucht, M Samara, S Heres, MX Patel, SW Woods, JM Davis Schizophrenia bulletin 40 (2), 314-326, 2014 | 368 | 2014 |
| Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis MT Samara, M Dold, M Gianatsi, A Nikolakopoulou, B Helfer, G Salanti, ... JAMA psychiatry 73 (3), 199-210, 2016 | 345 | 2016 |
| Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method S Leucht, M Samara, S Heres, MX Patel, T Furukawa, A Cipriani, ... Schizophrenia bulletin 41 (6), 1397-1402, 2015 | 271 | 2015 |
| Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis B Helfer, MT Samara, M Huhn, E Klupp, C Leucht, Y Zhu, RR Engel, ... American Journal of Psychiatry 173 (9), 876-886, 2016 | 252 | 2016 |
| The longitudinal course of schizophrenia across the lifespan: clinical, cognitive, and neurobiological aspects U Heilbronner, M Samara, S Leucht, P Falkai, TG Schulze Harvard review of psychiatry 24 (2), 118-128, 2016 | 175 | 2016 |
| Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review MT Samara, C Leucht, MM Leeflang, IG Anghelescu, YC Chung, ... American journal of psychiatry 172 (7), 617-629, 2015 | 167 | 2015 |
| Antipsychotic drugs: from receptor-binding profiles to metabolic side effects S Siafis, D Tzachanis, M Samara, G Papazisis Current neuropharmacology 16 (8), 1210-1223, 2018 | 164 | 2018 |
| Combining randomized and non‐randomized evidence in network meta‐analysis O Efthimiou, D Mavridis, TPA Debray, M Samara, M Belger, GCM Siontis, ... Statistics in medicine 36 (8), 1210-1226, 2017 | 158 | 2017 |
| Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies TA Furukawa, SZ Levine, S Tanaka, Y Goldberg, M Samara, JM Davis, ... JAMA psychiatry 72 (1), 14-21, 2015 | 121 | 2015 |
| How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials MT Samara, A Nikolakopoulou, G Salanti, S Leucht Schizophrenia bulletin 45 (3), 639-646, 2019 | 108 | 2019 |
| Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders M Dold, MT Samara, C Li, M Tardy, S Leucht Cochrane Database of Systematic Reviews, 2015 | 108 | 2015 |
| Equipercentile linking of scales measuring functioning and symptoms: examining the GAF, SOFAS, CGI-S, and PANSS MT Samara, RR Engel, A Millier, J Kandenwein, M Toumi, S Leucht European Neuropsychopharmacology 24 (11), 1767-1772, 2014 | 69 | 2014 |
| Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis G Kalopitas, C Antza, I Doundoulakis, A Siargkas, E Kouroumalis, ... Nutrition 83, 111092, 2021 | 61 | 2021 |
| Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination B Helfer, A Prosser, MT Samara, JR Geddes, A Cipriani, JM Davis, ... BMC medicine 13, 1-8, 2015 | 60 | 2015 |
| Systematic review with meta‐analysis: the effect of vitamin E supplementation in adult patients with non‐alcoholic fatty liver disease A Vadarlis, C Antza, DR Bakaloudi, I Doundoulakis, G Kalopitas, ... Journal of Gastroenterology and Hepatology 36 (2), 311-319, 2021 | 58 | 2021 |
Stefan LeuchtProf. Dr. med., Klinik für Psychiatrie und Psychotherapie der TU-MünchenVerified email at lrz.tum.de
